Erythema

·MeSH: Erythema

96 drugs in development·48 companies·1 clinical trial

Drug Pipeline by Phase

Approved(2)

Drug	Company
thalomid	CELGENE CORP /DE/ (CELG)
triamcinolone acetonide	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(26)

Drug	Company
AZD0120	ASTRAZENECA PLC (AZN)
biib059	BIOGEN INC. (BIIB)
cenerimod	Innovation Pharmaceuticals Inc. (IPIX)
Cenerimod	Crinetics Pharmaceuticals, Inc. (CRNX)
dapirolizumab pegol	BIOGEN INC. (BIIB)
dapirolizumab pegol	POINT Biopharma Global Inc. (PNT)
dapirolizumab pegol	GT Biopharma, Inc. (GTBP)
Dapirolizumab Pegol	NEKTAR THERAPEUTICS (NKTR)
dnth212	Dianthus Therapeutics, Inc. /DE/ (DNTH)
dzp	POINT Biopharma Global Inc. (PNT)
dzp	GT Biopharma, Inc. (GTBP)
ESK-001	ALUMIS INC. (ALMS)
fludarabine	Juno Therapeutics, Inc. (JUNO)
Fludarabine	BRISTOL MYERS SQUIBB CO (BMY)
ianalumab	Novartis AG (NVS)
Ianalumab	Novartis AG (NVS)
ianalumab s.c. q12w	Novartis AG (NVS)
ianalumab s.c. q4w	Novartis AG (NVS)
kite-439	Kite Pharma, Inc. (KITE)
kite-585	Kite Pharma, Inc. (KITE)
kite-718	Kite Pharma, Inc. (KITE)
kite-796	Kite Pharma, Inc. (KITE)
Litifilimab	BIOGEN INC. (BIIB)
Medi-546	ASTRAZENECA PLC (AZN)
sar448501	Sanofi (SNYNF)
UCAR-T cells	Filana Therapeutics Inc. (FLNA)

Phase 2(29)

Drug	Company
afimetoran	BRISTOL MYERS SQUIBB CO (BMY)
alpn-101	ALPINE IMMUNE SCIENCES, INC. (ALPN)
anifrolumab	Valneva SE (VALN)
AUCATZYL/obe-cel	Autolus Therapeutics plc (AUTL)
belimumab 10mg/kg	GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
cc-97540	Juno Therapeutics, Inc. (JUNO)
CC-97540	BRISTOL MYERS SQUIBB CO (BMY)
cd19	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
cfz533	Novartis AG (NVS)
daxdilimab	AMGEN INC (AMGN)
dovramilast	MEDICINES CO /DE (MDCO)
glpg3667	Galapagos NV (GLPG)
GLPG3667	Galapagos NV (GLPG)
iberdomide	CELGENE CORP /DE/ (CELG)
imvotamab	IGM Biosciences, Inc. (IGMS)
inebilizumab	AMGEN INC (AMGN)
mb-cart19.1	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
MK-1045	Merck & Co., Inc. (MRK)
obecabtagene autoleucel	Autolus Therapeutics plc (AUTL)
prv-3279	Sanofi (SNY)
prv-3279	Sanofi (SNYNF)
prv-3279	PROVENTION BIO, INC. (PBI)
PRV-3279	MACROGENICS INC (MGNX)
rese-cel	Cabaletta Bio, Inc. (CABA)
sar441344 iv	Sanofi (SNYNF)
sar441344 iv	Sanofi (SNY)
sar441344 sc	Sanofi (SNY)
sar441344 sc	Sanofi (SNYNF)
sar443122	Sanofi (SNY)

Phase 1(21)

Drug	Company
abbv-519	AbbVie Inc. (ABBV)
ALLO-329	Allogene Therapeutics, Inc. (ALLO)
AZD0120	Merus N.V. (MRUS)
blinatumomab	AMGEN INC (AMGN)
cenerimod	Viatris Inc (VTRS)
cnty-101	Century Therapeutics, Inc. (IPSC)
cnty-308	Century Therapeutics, Inc. (IPSC)
cnty-341	Century Therapeutics, Inc. (IPSC)
cnty-813	Century Therapeutics, Inc. (IPSC)
il-2	Century Therapeutics, Inc. (IPSC)
itolizumab [bmab 600]	Equillium, Inc. (EQ)
LUCAR-G79D T cells	Legend Biotech Corp (LEGN)
lymphodepleting chemotherapy	Century Therapeutics, Inc. (IPSC)
pit565	Novartis AG (NVS)
pit565	Novartis AG (NVS)
prula-cel	Adicet Bio, Inc. (ACET)
pt101	Pandion Therapeutics, Inc. (PAND)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio, Inc. (CABA)
sar448501	Sanofi (SNY)
sc291	Sana Biotechnology, Inc. (SANA)
tocilizumab	Juno Therapeutics, Inc. (JUNO)

Preclinical(4)

Drug	Company
eb201	Estrella Immunopharma Inc. (ESLA)
gri-0803	GRI Bio, Inc. (GRI)
inb-619	IN8BIO, INC. (INAB)
IRF5 program	ALUMIS INC. (ALMS)

Phase 1/Phase 2(9)

Drug	Company
alpn-303	ALPINE IMMUNE SCIENCES, INC. (ALPN)
anti-cd19 car t cell therapy	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
descartes-08	Cartesian Therapeutics, Inc. (RNAC)
Fludarabine	ASTRAZENECA PLC (AZN)
gc012f	SQZ Biotechnologies Co (SQZB)
rapcabtagene autoleucel	Novartis AG (NVS)
ytb323	Novartis AG (NVS)
YTB323	Novartis AG (NVS)
zugo-cel	CRISPR Therapeutics AG (CRSP)

Phase 2/Phase 3(2)

Drug	Company
AZD5492	ASTRAZENECA PLC (AZN)
imvt-1402	Roivant Sciences Ltd. (ROIV)

Phase 4(3)

BioSniper tracks 96 drugs in development for Erythema across 48 companies.

There are 1 clinical trial targeting Erythema tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.